Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Vividion Therapeutics initiates the phase I clinical trial in advanced solid tumors utilizing KEAP1 activator
Latest Hotspot
3 min read
Vividion Therapeutics initiates the phase I clinical trial in advanced solid tumors utilizing KEAP1 activator
21 September 2023
Vividion Therapeutics, Inc., confirmed the commencement of patient dosing for a Phase I cancer clinical trial concerning its experimental oral agent, KEAP1 activator VVD-130037.
Read →
Deep Scientific Insights on Vildagliptin's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on Vildagliptin's R&D Progress, Mechanism of Action, and Drug Target
21 September 2023
This article summarized the latest R&D progress of Vildagliptin, the Mechanism of Action for Vildagliptin, and the drug target R&D trends for Vildagliptin.
Read →
Review and Prospects of CYP1A2 Inhibitors
Review and Prospects of CYP1A2 Inhibitors
21 September 2023
Recombinant Cytochrome P450 1A2 (CYP1A2) belongs to the CYP1A subfamily of the CYP1 family and is encoded by the CYP1A2 gene.
Read →
An In-depth Analysis of Sotagliflozin's R&D Progress and Mechanism of Action on Drug Target
Drug Insights
5 min read
An In-depth Analysis of Sotagliflozin's R&D Progress and Mechanism of Action on Drug Target
21 September 2023
This article summarized the latest R&D progress of Sotagliflozin, the Mechanism of Action for Sotagliflozin, and the drug target R&D trends for Sotagliflozin.
Read →
The first patient receives treatment from NeuroBo Pharmaceuticals in their Phase 2a Clinical Trial studying DA-1241
Latest Hotspot
3 min read
The first patient receives treatment from NeuroBo Pharmaceuticals in their Phase 2a Clinical Trial studying DA-1241
21 September 2023
NeuroBo Pharmaceuticals, Inc. has started its Phase 2a clinical trial using DA-1241, a unique GPR119 agonist, to treat the first patient with nonalcoholic steatohepatitis.
Read →
 Selumetinib: Detailed Review of its Transformative R&D Success
Drug Insights
4 min read
Selumetinib: Detailed Review of its Transformative R&D Success
21 September 2023
This article summarized the latest R&D progress of Selumetinib, the Mechanism of Action for Selumetinib, and the drug target R&D trends for Selumetinib.
Read →
Important Research Area in Life Science: Growth Factors
Advanced Tech.
7 min read
Important Research Area in Life Science: Growth Factors
21 September 2023
Growth factors represent a class of polypeptides that regulate cell growth and various other cellular functions through binding with specific, high-affinity cell membrane receptors.
Read →
Peramivir Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Peramivir Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
20 September 2023
This article summarized the latest R&D progress of Peramivir, the Mechanism of Action for Peramivir, and the drug target R&D trends for Peramivir.
Read →
The US has sanctioned Ojjaara (momelotinib), the the first and only therapeutic agent for anemia
Latest Hotspot
3 min read
The US has sanctioned Ojjaara (momelotinib), the the first and only therapeutic agent for anemia
20 September 2023
GSK plc has confirmed that Ojjaara(momelotinib), a daily oral JAK1/JAK2 and activin A receptor type 1 inhibitor, has received approval from the US FDA.
Read →
Unleashing the Power of Pantethine: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Pantethine: A Comprehensive Review on R&D Breakthroughs
20 September 2023
This article summarized the latest R&D progress of Pantethine, the Mechanism of Action for Pantethine, and the drug target R&D trends for Pantethine.
Read →
An effective method to ward off viral intrusions: Toxoid Vaccine
Advanced Tech.
5 min read
An effective method to ward off viral intrusions: Toxoid Vaccine
20 September 2023
Toxoid Vaccine is essentially a bacterial toxin that is rendered harmless due to processing.
Read →
 A Comprehensive Review of Pacritinib's R&D Innovations and Drug Target Mechanism
Drug Insights
5 min read
A Comprehensive Review of Pacritinib's R&D Innovations and Drug Target Mechanism
20 September 2023
This article summarized the latest R&D progress of Pacritinib, the Mechanism of Action for Pacritinib, and the drug target R&D trends for Pacritinib.
Read →